Description
Trazodone hydrochloride exhibits antidepressant, anxiolytic, and hypnotic activity. Trazodone hydrochloride inhibits 5-HT2 receptors, α1/2-adrenergic receptors, histamine receptors, and serotonin transporters (SERT), and also acts as a partial agonist at 5-HT1A receptors. Although trazodone hydrochloride is clinically acceptable for treatment of anxiety, depression, and insomnia, it is also often used to treat erectile dysfunction due to its inhibition of adrenergic receptors. In addition to its modulation of neurotransmitters, this compound also weakly inhibits voltage-gated K+ channels, binding to closed channels and accelerating inactivation of open channels.
References
Chae YJ, Choi JS, Hahn SJ. Inhibition of Kv4.3 potassium channels by trazodone. Naunyn Schmiedebergs Arch Pharmacol. 2013 Aug;386(8):711-9. PMID: 23615873.
Odagaki Y, Toyoshima R, Yamauchi T. Trazodone and its active metabolite m-chlorophenylpiperazine as partial agonists at 5-HT1A receptors assessed by [35S]GTPgammaS binding. J Psychopharmacol. 2005 May;19(3):235-41. PMID: 15888508.
Otani K, Yasui N, Kaneko S, et al. Trazodone treatment increases plasma prolactin concentrations in depressed patients. Int Clin Psychopharmacol. 1995 Jun;10(2):115-7. PMID: 7673654.
Haria M, Fitton A, McTavish D. Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders. Drugs Aging. 1994 Apr;4(4):331-55. PMID: 8019056.
Marek GJ, McDougle CJ, Price LH, et al. A comparison of trazodone and fluoxetine: implications for a serotonergic mechanism of antidepressant action. Psychopharmacology (Berl). 1992;109(1-2):2-11. PMID: 1365657.
Scharf MB, Sachais BA. Sleep laboratory evaluation of the effects and efficacy of trazodone in depressed insomniac patients. J Clin Psychiatry. 1990 Sep;51 Suppl:13-7. PMID: 2211559.
